1,010
Participants
Start Date
September 13, 2017
Primary Completion Date
January 31, 2022
Study Completion Date
June 21, 2022
Regorafenib (Stivarga, BAY73-4506)
As per the treating physicians discretion
C.R.Wood Cancer Center, Glen Falls Hospital, Glens Falls
Roswell Park Cancer Institute, Buffalo
Corporal Michael J. Crescenz VA Medical Center, Philadelphia
Einstein Medical Center, Philadelphia
Mercy Medical Center, Baltimore
University of Florida Health, Gainesville
University of Louisville - Clinical Trials Unit, Louisville
University of Cincinatti, Cincinnati
University of Michigan, Ann Arbor
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
University Medical Center, New Orleans
UT Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston
St. Joseph´s Hospital and Medical Center, Phoenix
Banner MD Anderson Cancer Center, Gilbert
Rutgers University, Newark
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Lead Sponsor
Bayer
INDUSTRY